Figure 1.
Study location.
Table 1.
Safety Outcomes and Assessments.
Figure 2.
Enrollment, randomization and workflow.
Table 2.
Baseline Characteristics in 143 Patients; intention to treat analysis.
Table 3.
Clinical and parasitological responses in 143 patients with acute P.falciparum malaria receiving artesunate monotherapy: intention to treat analysis.
Figure 3.
Modified intention-to-treat analysis: outcome measured to 42 days.
Table 4.
Outcome: per protocol analyses in patients at 28 (n = 136) and 42 (n = 133) days; P. vivax cases occurring during follow-up not removed.
Table 5.
Outcome: per protocol analysis in 109 patients at 42 days; P. vivax relapse cases censored from analysis.
Table 6.
Individual data for patients with reappearance of Plasmodium falciparum parasites during follow-up and median (IQR) values for cured subjects in the three dosing arms.
Figure 4.
Modified intention-to-treat analysis: proportion of patients remaining parasitemic by treatment arm.
Table 7.
Parasitological, clinical and in vitro responses in early treatment failures, recrudescent and cured patients; data expressed as median (IQR) unless otherwise stated.
Table 8.
Comparison of clinical and parasitological outcomes with other published data (Dondorp, 2009).
Table 9.
Comparison of clinical, parasitological and laboratory parameters of patients with rapid or slow parasite clearance.
Table 10.
Comparison of baseline and pharmacokinetic parameters with other published data (Dondorp, 2009).
Figure 5.
IC50 values at baseline using HRP2 methodology in fresh cultured parasite isolates from 131 patients.